Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple mye...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Richardson, Paul G., Oriol, Albert, Larocca, Alessandra, Bladé, Joan, Cavo, Michele, Rodriguez-Otero, Paula, Leleu, Xavier, Nadeem, Omar, Hiemenz, John W., Hassoun, Hani, Touzeau, Cyrille, Alegre, Adrián, Paner, Agne, Maisel, Christopher, Mazumder, Amitabha, Raptis, Anastasios, Moreb, Jan S., Anderson, Kenneth C., Laubach, Jacob P., Thuresson, Sara, Thuresson, Marcus, Byrne, Catriona, Harmenberg, Johan, Bakker, Nicolaas A., Mateos, María-Victoria
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2021
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078327/
https://ncbi.nlm.nih.gov/pubmed/33296242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02259
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados